The abstract describes the design of the SHELL and ELSA trials evaluating lacidipine for preventing cardiovascular events and organ damage in hypertensive patients, with no results reported.
Does lacidipine-based treatment prevent cardiovascular events and organ damage compared to chlorthalidone or atenolol in hypertensive patients?
This paper outlines the rationale and design of the SHELL and ELSA trials, which aim to evaluate the cardiovascular and organ-protective benefits of lacidipine in hypertensive patients.
AIMS: To assess the benefits of the calcium antagonist lacidipine on the prevention of cardiovascular events and the prevention of organ damage in two long-term clinical trials. SYSTOLIC HYPERTENSION IN THE ELDERLY LONG-TERM LACIDIPINE (SHELL) TRIAL: In the SHELL trial, the efficacy of lacidipine-based treatment is to be compared with that of thiazide-like diuretic (chlorthalidone)-based treatment in elderly patients with isolated systolic hypertension. The incidence of cardiovascular mortality and cardiovascular morbidity over a 5-year period are endpoints. EUROPEAN LACIDIPINE STUDY ON ATHEROSCLEROSIS (ELSA) TRIAL: In the ELSA trial, the effects of lacidipine-based treatment and beta-blocker (atenolol)-based treatment on the development and progression of carotid atherosclerosis are to be assessed in hypertensive patients. The primary endpoint of this study is the rate of change in the thickness of the carotid artery wall, measured with B-mode ultrasound.
Alberto Zanchetti (Fri,) conducted a review in Hypertension. Lacidipine vs. Chlorthalidone (SHELL) or Atenolol (ELSA) was evaluated on Cardiovascular mortality and morbidity (SHELL); rate of change in carotid artery wall thickness (ELSA). The abstract describes the design of the SHELL and ELSA trials evaluating lacidipine for preventing cardiovascular events and organ damage in hypertensive patients, with no results reported.